Virtus Investment Advisers, Inc. has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $119 Million distributed in 340 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Icici Bank LTD with a value of $3.75M, Virtus ETF Tr Ii Virtus Duff & with a value of $2.89M, Janus Detroit Str Tr Janus Hen with a value of $2.19M, Microsoft Corp with a value of $2.06M, and Taylor Morrison Home Corp with a value of $1.92M.
Examining the 13F form we can see an increase of $7.76M in the current position value, from $112M to 119M .
Virtus Investment Advisers, Inc. is based out at Hartford, CT
Below you can find more details about Virtus Investment Advisers, Inc. portfolio as well as his latest detailed transactions.
Portfolio value
$119 Million
Technology: $22.9 Million
Financial Services: $19.3 Million
Healthcare: $19 Million
Industrials: $18.3 Million
Consumer Cyclical: $13.3 Million
Consumer Defensive: $7.09 Million
ETFs: $5.08 Million
Utilities: $4.68 Million
Other: $9.71 Million
Stock
Market Cap.
Holding Value (Reported)
# of Shares.
Last Trade
Trade History
$17B
$76,000
0.06% of portfolio
467
Q2 2024
Reduced 34.13%
$1.31B
$70,000
0.06% of portfolio
6,807
Q2 2024
Reduced 84.5%
$44.9B
$67,000
0.06% of portfolio
740
Q3 2024
New
$705M
$67,000
0.06% of portfolio
6,156
Q3 2024
Reduced 82.24%
$83B
$61,000
0.05% of portfolio
535
Q2 2024
Reduced 34.19%
$105B
$59,000
0.05% of portfolio
266
Q2 2024
Reduced 34.16%
$213B
$62,000
0.05% of portfolio
70
Q2 2024
Reduced 33.96%
$802M
$30,000
0.03% of portfolio
2,973
Q3 2024
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q1 2024
New
-
$0
0.0% of portfolio
-
Q2 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
Added 275.0%
-
$0
0.0% of portfolio
-
Q1 2024
Added 14.29%
-
$0
0.0% of portfolio
-
Q3 2024
New
Halozyme Therapeutics Inc
-
$0
0.0% of portfolio
-
Q1 2024
New
-
$0
0.0% of portfolio
-
Q2 2024
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q1 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
Added 60.98%
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 55.17%
Alnylam Pharmaceuticals Inc
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
New
Biomarin Pharmaceutical Inc
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q2 2024
Added 40.0%
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 40.0%
-
$0
0.0% of portfolio
-
Q3 2024
New
Collegium Pharmaceutical Inc
-
$0
0.0% of portfolio
-
Q1 2024
New
-
$0
0.0% of portfolio
-
Q2 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 53.66%
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 42.24%
-
$0
0.0% of portfolio
-
Q4 2023
New
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 9.26%
-
$0
0.0% of portfolio
-
Q2 2024
Added 46.0%
Ventas Rlty LTD Partnership
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
New